What is the recommended dosing, monitoring, and contraindications for levosimendan in a post‑CABG patient with low‑output syndrome and an ejection fraction ≤35%?

Levosimendan in Post-CABG Low Output Syndrome

Perioperative levosimendan should be considered to reduce the risk of low cardiac output syndrome (LCOS) in patients with reduced LVEF undergoing isolated CABG (Class IIa recommendation), but its use for treating established post-CABG LCOS remains controversial with mixed evidence.

Current Guideline Recommendations

The most recent 2025 EACTS/EACTAIC/EBCP guidelines provide nuanced recommendations 1:

• Perioperative administration of levosimendan should be considered to reduce the risk of LCOS in patients with reduced LVEFs undergoing isolated CABG (Class IIa, Level A evidence)
• Perioperative administration of levosimendan may be considered to improve survival following cardiac surgery in patients with poor LV function and perioperative LCOS (Class IIb, Level B evidence)
• Positive inotropes and/or vasopressors are recommended as first-line medical treatment in patients with LCOS during cardiac surgery (Class I, Level A evidence)

The 2019 EACTS guidelines were more restrictive 2:

• Prophylactic infusion of levosimendan to reduce adverse events and mortality is not recommended (Class III, Level A)
• Adding levosimendan to other positive inotropes or vasopressors in patients requiring hemodynamic support after cardiac surgery is not recommended (Class III, Level B)

Dosing Recommendations

For Prophylactic Use (Preoperative/Perioperative)

Based on the evidence and clinical practice patterns 3:

Standard dosing protocol:

• Loading dose: 24 μg/kg over 10 minutes administered before cardiopulmonary bypass, OR
• Continuous infusion: 0.1 μg/kg/min for 24 hours without loading dose (to minimize hypotension risk)

Low-dose individualized approach (emerging evidence) 4:

• Initial dose: 1.25 mg (approximately 0.018 mg/kg for 70 kg patient) after anesthesia induction
• Additional 1.25 mg increments postoperatively based on hemodynamic response
• 73% of patients required ≤5 mg cumulative dose

For Treatment of Established LCOS

If used therapeutically (despite limited guideline support):

• Infusion rate: 0.1 μg/kg/min for 24 hours
• Avoid loading dose in hemodynamically unstable patients to prevent hypotension
• Can be combined with other inotropes (norepinephrine, dobutamine) 3

Monitoring Requirements

Essential hemodynamic monitoring:

• Continuous arterial blood pressure monitoring (central line preferred)
• Cardiac output/cardiac index measurement (Swan-Ganz catheter or less invasive methods)
• Central venous oxygen saturation (ScvO2) or mixed venous saturation (SvO2)
• Lactate clearance
• Transthoracic or transesophageal echocardiography for ventricular function assessment 3

Specific parameters to track:

• Target cardiac index: >2.2 L/min/m²
• Target SvO2: >65%
• Lactate: Trending downward
• Systolic blood pressure: Maintain >90 mmHg (may require concurrent vasopressor)

Monitoring frequency:

• Continuous: BP, heart rate, ECG
• Every 1-2 hours initially: Cardiac output, lactate, ScvO2
• Daily: Renal function, electrolytes (particularly potassium)

Contraindications and Precautions

Absolute contraindications:

• Severe hypotension (SBP <85 mmHg) without vasopressor support
• Mechanical obstruction affecting ventricular filling or outflow (severe aortic stenosis, hypertrophic obstructive cardiomyopathy)
• Severe tachyarrhythmias
• History of torsades de pointes

Relative contraindications/cautions:

• Moderate hypotension (SBP 85-100 mmHg) - requires concurrent vasopressor 5
• Severe renal impairment (use with caution, no dose adjustment needed)
• Severe hepatic impairment
• Atrial fibrillation with rapid ventricular response (may increase heart rate)

Key adverse effects to monitor:

• Hypotension (most common - occurs in 14-57% of patients) 3
• Tachycardia and atrial fibrillation (though evidence suggests reduced AF incidence compared to dobutamine) 3
• Headache
• Hypokalemia (monitor and replace aggressively)

Evidence-Based Clinical Context

The Controversy: Prophylactic vs. Therapeutic Use

Recent large trials showed NO benefit for prophylactic levosimendan:

The LEVO-CTS trial (2017) 6 and LICORN trial (2017) 7 - both large multicenter RCTs - found no reduction in the composite endpoint of death, renal replacement therapy, myocardial infarction, or mechanical support with prophylactic levosimendan in mixed surgical populations.

However, subgroup analyses revealed important distinctions:

A pooled analysis 8 of these trials demonstrated:

• Isolated CABG patients: 61% reduction in 90-day mortality (HR 0.39,95% CI 0.19-0.82, p=0.013)
• Combined CABG + valve surgery: No benefit, possible harm (HR 1.73,95% CI 0.77-3.92)

This explains the 2025 guideline upgrade to Class IIa recommendation specifically for isolated CABG patients 1.

Comparative Advantages Over Other Inotropes

Levosimendan demonstrates several advantages compared to catecholamines 3:

• Reduced myocardial oxygen consumption (unlike dobutamine/epinephrine)
• Lower incidence of postoperative atrial fibrillation compared to dobutamine
• Reduced postoperative myocardial infarction (0% vs 40% with amrinone in one study)
• Decreased ICU length of stay and time to extubation
• Improved renal function - reduced acute kidney injury risk 9
• Cardioprotective properties beyond inotropic effects (anti-inflammatory, antioxidant) 3

When LCOS Develops Despite Prophylaxis

If LCOS develops in your post-CABG patient with EF ≤35% 10:

1. First-line: Traditional inotropes/vasopressors (dobutamine, norepinephrine) remain Class I recommendation 1
2. Consider adding levosimendan only in selected difficult-to-wean patients (Class IIb) 2
3. Do NOT add levosimendan to existing inotrope/vasopressor regimens as routine practice (Class III recommendation from 2019 guidelines) 2

Practical Clinical Algorithm

For post-CABG patient with EF ≤35% and established LCOS:

1. Optimize volume status first - ensure adequate preload using dynamic parameters (stroke volume variation, pulse pressure variation) 3

2. Initiate standard inotropic support:

   • Norepinephrine (if SBP <90 mmHg) + dobutamine, OR
   • Phosphodiesterase III inhibitor (milrinone)

3. If inadequate response after 6-12 hours:

   • Consider levosimendan 0.1 μg/kg/min × 24 hours (no loading dose)
   • Maintain concurrent vasopressor support to prevent hypotension
   • Target SBP >90 mmHg, CI >2.2 L/min/m²

4. If still inadequate response:

   • Escalate to mechanical circulatory support (IABP, ECMO, Impella)
   • Consult advanced heart failure team

Common Pitfalls to Avoid

1. Using loading dose in unstable patients - causes profound hypotension; omit loading dose in LCOS treatment
2. Stopping vasopressors prematurely - levosimendan causes vasodilation; maintain BP support
3. Using in combined valve + CABG surgery - evidence suggests no benefit or possible harm 8
4. Adding to maximal inotropic support - 2019 guidelines recommend against this (Class III) 2
5. Inadequate potassium monitoring - levosimendan can cause hypokalemia; maintain K+ >4.0 mEq/L
6. Expecting immediate effect - peak hemodynamic effects occur at 24-48 hours due to active metabolites

Quality of Life and Mortality Considerations

The most recent meta-analysis 9 in isolated CABG patients with severe LV dysfunction (EF <35%) demonstrated:

• 69% reduction in all-cause mortality (RR 0.31)
• 56% reduction in acute kidney injury (RR 0.44)
• 55% reduction in LCOS (RR 0.45)
• 51% reduction in postoperative atrial fibrillation (RR 0.49)

These mortality and morbidity benefits support the 2025 guideline upgrade for prophylactic use in isolated CABG, but evidence remains insufficient for routine therapeutic use in established LCOS 1.